). Genistin and daidzin are relatively large molecules; they are very water-soluble and highly polar. These properties hinder their absorption from the gastrointestinal tract and therefore the bioavailability of the estrogen moiety.
To be absorbed and rendered bioavailable, the SIs must be hydrolyzed to aglycons, i.e. separated from the glucoside component 7. This takes place by the action of special enzymes, the glycosidases. However, the human gastrointes tinal tract and that of many mammalians does not secrete glycosidases and therefore the isoflavones cannot be hydro lyzed to become bioavailable. Conversely, some micro organisms of the intestinal flora and in particular some lactic acid bacteria, produce the glycosidases required for the mentioned hydrolytic process that is necessary for the absorption of the SIs 8, 9. The presence of glycosidase producing bacteria in the gastrointestinal tract is therefore the prerequisite for the absorption and the efficacy of the SIs.
The intestinal flora varies greatly between individuals and, even in the same Subject, it varies in function of the diet, climate, drug therapies, diseases, etc. Thus, in many Sub jects, the glycosidase production by the intestinal flora can be scarce or even absent, jeopardizing the absorption of the SIS.
Object of the present invention is to provide a composi tion for oral administration, particularly as a dietary Supple ment, for the mitigation, relief, and/or prevention of climac teric and postmenopausal disorders affecting women in pre-, peri-and post-menopause, including dismetabolism of bones that causes bone loss and structural changes with an increases of fracture risk.
SUMMARY OF THE INVENTION
The present invention provides a composition for the relief and prevention of climacteric and postmenopausal The composition includes Soy isoflavones with estrogenic activity and lactic acid bacteria to produce glycosidases in the intestine, aimed to split the ingested isoflavone gluco sides into the aglycons that can be absorbed and to insure in all subjects the bioavailability of the administered SIs.
The invention also provides a method for the relief and prevention of climacteric and menopausal disorders, com prising the oral administration of an effective amount of the above mentioned composition to an individual in need thereof.
In principle, any type of lactic acid bacteria is suitable for the composition of the invention. In fact, lactic acid bacteria are probiotics that provide several benefits, because:
They produce lactic acid that acidifies the intestinal content creating adverse condition for the growth of several pathogenic micro-organisms (Coli, Candida, etc.) and, conversely, creating favourable conditions for the absorption of calcium, of iron, of phosphorus and of other nutrients.
By these mechanisms, and through the lowering of pH resulting from the production of lactic acid, the lactic acid bacteria improve and balance the intestinal flora. This is very useful, especially when the intestinal flora is deficient or unbalanced, as a result of incorrect diet, of drugs (especially antibiotics), of climatic stresses, of digestive disorders or deficiencies. In fact, these con ditions cause diarrhea, constipation, flatulence, maldi gestion, asthenia and malaise due to the toxins pro duced by the predominance of the putrefactive over the fermenting flora. The lactic acid bacteria produce proteases and lipases that complete the digestion of proteins and fats and Subtract also these nutrients from the micro-organisms of the intestinal flora that produce toxic Substances, e.g. those derived from the anaerobic processes of putrefaction. The lactic acid bacteria produce vitamin K, a factor that is necessary for blood clotting, and also several Vita mins of group B, required for the energetic metabolism. They eliminate intestinal dysmicrobisms, also because they produce special antibacterial Substances, the bac teriocins, which impede the growth of the "bad" flora. Moreover, the lactic acid bacteria grow and multiply on the intestinal wall, forming a barrier against pathogenic micro-organisms. Such as Candida albicans, Salmonel lae, Escherichiae, Staphylococci, Clostridia, etc., which produce toxins and can cause intestinal infec tions.
Finally, the lactic acid bacteria stimulate the immune defences of the gastrointestinal tract, helping to defend our body against infections and toxic allergens. For the purposes of the invention, lactic acid bacteria consisting of Lactobacillus sporogenes (Bacillus coagul lans), hereinafter abbreviated as LS, is particularly preferred, because the spores of LS are stable in normal environmental conditions, do not need storage in refrigerator and remain viable in the gastric and biliary secretions that kill most of the other lactic acid bacteria.
The LS, in particular, produces by a homofermentative process L-lactic acid, i.e. the isomer that enters in our metabolic pathways and is recommended by the World Health Organization because it does not create a systemic acidosis.
For the production of lactic acid, LS utilizes the undi gested fragments of Sugars, Subtracting these substrates from 3 other harmful species of the intestinal flora, thus hindering their growth and contributing furthermore to the general well being.
For all these reasons, the lactic acid bacteria and in particular the LS, are very beneficial probiotic agents that, in addition to enhancing the bioavailability of the SIs, provide several benefits for the general well-being.
A
The goal of the experimental part was to investigate the role of the different ingredients in the prevention of bone loss in ovariectomized rats, a well-known model of post menopausal osteoporosis 6.
Briefly, 95 days old Sprague-Dawley rats were ovariec tomized under equitesin anaesthesia 3 ml/kg body weight intraperitoneal (equitesin is a mixture of pentobarbital, etha nol, chloral hydrate, propylene glycol, magnesium Sulphate dissolved in water). The animals were divided into 4 groups of 8 animals each. A 5" group of 8 animals was sham operated and kept as non-ovariectomized controls. The rats had free access to water and were fed ad libitum with Harlan diet for rodents enriched with calcium carbonate (0.1 g/kg diet) and cholecalciferol (1 g/kg diet). SIS and LS were suspended in 0.5% hy-droxy-propyl-methyl-cellulose in water, hereinafter called VEHICLE, and daily administered with gastric tube in a dose of 10 ml/kg body weight.
The groups were treated as follows. The doses were based on those generally recommended for human use, adapting them to the body weight of the rats used in the study.
Soy isoflavones: the usual daily doses are 20-80 mg. preferably 40-60 mg.
Lactobacillus sporogenes: the usual daily doses are 75-750 million spores, preferably 250-500 million.
Horsetail: the usual daily doses are equivalent to 3-10 mg silicon dioxide.
Calcium: The Recommended Daily Dietary Allowance (RDDA) in adult women is 800 mg. For the purposes of the invention, a daily dose from 100 to 300 mg is preferred, as Supplement to the calcium contained in the normal diet. Six weeks after ovariectomy, the rats were killed by cervical dislocation under ether anesthesia. The uteri were extracted an immediately weighed, the femurs were freed from the Soft tissues, their length was measured with a calliper, volume and density were measured by Archimedes principle, then they were ashed for 24 h at 640° C. Each ash sample was weighed and dissolved in 6 NHC1. Calcium was measured in the resulting solution by atomic absorption spectrophotometry and phosphorus by calorimetric analysis. The averages and standard errors of the different results were calculated and the significance between values esti mated by Student's t-test.
The results obtained at the end of the study are reported in Table 1 and can be summarized as follows.
1. Six weeks after ovariectomy there was no significant change of body weight in any of the ovariectomized animal groups vs. sham operated animals (Group 1).
2. Conversely, in the ovariectomized controls (Group 2) there was a very significant decrease of the weight of uterus and a significant decrease in the length, density, ash weight, calcium and phosphorus content of the femurs, showing the negative effects of the estrogen deficiency on bone trophism.
3. The administration of SIs (Group 3) had no significant effects (vs. Group 2) on body weight and on uterus (absence of Stimulation of alpha estrogen receptors), but increased significantly the femoral length and the bone phosphorus, showing a moderate positive effect on bone trophism.
4. The addition of Ls to SIs (Group 4) notably and Surprisingly improved bone trophism, as shown by the significant increase of all bone trophism markers (femur length, density, ash weight, calcium and phosphorus con tent), Supporting the rationale of the SIS-LS combination to enhance the positive effects of the SIs on bone by favouring the bioavailability of the SIs.
5. The further addition of Horsetail extract (Group 5) elicited a further unexpected improvement in all bone tro phism markers (femur length, density, ash weight, calcium and phosphorus content), confirming the anabolic effects of this natural herbal product on the bone.
In conclusion, LS remarkably strengthens the anabolic effects of SIs on the bone, due to the enhancement of the bioavailability of SIs and to the enhancement of intestinal calcium and phosphorus absorption elicited by the probiotic properties of Ls. The addition of Horsetail extract promotes a further beneficial effect on bone anabolism. Notably, neither SIs nor SIs+Ls, had significant effects on the weight of uterus, showing the absence of the stimulation of the alpha estrogen receptors. This is an important contrast with the effects elicited by estrogen hormones, which enhance bone trophism but may cause in some patients unwanted effects, especially by prolonged use, due to the stimulation of the alpha estrogen receptors by these agents. The study supports therefore the rationale of the SIs--Ls combination as a natural and well tolerated treatment to prevent bone loss due to the deficiency of estrogen hor mones caused by ovariectomy in the rat, which occurs also in women after menopause. The addition of Horsetail extract reinforces the prevention of bone loss elicited by the SIs--Ls combination. Sachets Containing Powder for Extemporaneous Oral Suspension
The following formulation regards the active ingredients and the excipients (with their technical functions) that can be used to formulate a powder Suitable to prepare an oral Suspension.
The daily dose is carried in a single portion of powder. The portions are contained in Sachets consisting of an external paper layer, an aluminium interface and an internal polyethylene layer. The Sachets are prepared according to the current technical knowledge and without the need of any particular or special procedure. In Summary the following production steps are requested:
weighing of the individual ingredients; homogenisation of the ingredients in a blender Suitable for the dry mixing operations; thermoforming of the Sachets in a suitable automatic line including filling and sealing thereof as well; filling and sealing of the sachets on the above described automatic line to obtain Sachets of the desired size and shape, containing the monodose powder for extempo aOUS US.
The needed ingredients are listed in the following Tables. 10 extract in a daily dose is from 5 to 7 mg expressed as silicon dioxide contained in said dry extract.
11. A method for treatment of climacteric and menopausal disorders affecting women in pre-, peri-and post-meno pause, comprising orally administering an effective amount of a composition comprising soy isoflavones and viable lactic acid bacteria comprising at least Lactobacillus sporo genes (Bacillus coagulans), wherein the composition is provided in pharmaceutical dosage forms for oral adminis tration.
12. A method for the treatment according to claim 11, for the treatment of the bone loss that may follow menopause or other forms of ovarian insufficiency.
13. A method for treatment of climacteric and menopausal disorders affecting women in pre-, peri-and post-menopause according to claim 11, wherein the lactic acid bacteria consists of Lactobacillus sporogenes (Bacillus coagulans).
14. A method for treatment of climacteric and menopausal disorders affecting women in pre-, peri-and post-menopause according to claim 11 or 13, the composition further com prising Equisetum arvense dry extract.
15. A method for treatment of climacteric and menopausal disorders affecting women in pre-, peri-and post-menopause according to claim 11 or 13, wherein the composition is in tablet form.
16. A method for treatment of climactenic and meno pausal disorders affecting women in pre-, peri-and post menopause according to claim 14, wherein the composition is in tablet form.
